Anthrax, an infectious disease caused by the bacterium Bacillus anthracis, is often treatable in its early stages. But once ...

University of Pittsburgh researchers discovered that a mix of growth factors can rescue cells from late-stage anthrax damage ...

The work entitled “ Semen podocarpi extract enhances radiosensitivity in nasopharyngeal carcinoma cells via Raf/MEK/ERK ...

Anthrax, an infectious disease caused by the bacterium Bacillus anthracis, is often treatable in its early stages. But once ...

Studying the early development of human embryos is challenging due to ethical constraints and technical difficulties.

Mutations in the RAS-RAF-MEK-ERK pathway that drive many forms of human malignancies. In particular, the serine/threonine kinase BRAF is mutated in ~8% of all cancers. Targeted inhibitors have been ...

The laboratory is studying small molecules that selectively inhibit the components of RAS-RAF-MEK-ERK and PI3K-AKT-mTOR pathways. These compounds are being used as reagents to define the role of these ...

Results provide proof-of-concept that ERK pathway reactivation might be an effective, biologically based therapy to prevent anthrax-induced lethality.

A new review was published in , Volume 16, on March 13, 2025, titled "Signaling pathway dysregulation in breast cancer." ...

Influenza and some other RNA viruses rely on the Raf/MEK/ERK signaling pathway inside human cells to replicate. Atriva’s lead candidate, ATR-002, is a small-molecule inhibitor of MEK ...